Last $2.42 USD
Change Today +0.005 / 0.21%
Volume 48.0K
UPI On Other Exchanges
Symbol
Exchange
NASDAQ CM
Berlin
As of 8:10 PM 11/21/14 All times are local (Market data is delayed by at least 15 minutes).

uroplasty inc (UPI) Snapshot

Open
$2.45
Previous Close
$2.41
Day High
$2.50
Day Low
$2.41
52 Week High
01/24/14 - $5.40
52 Week Low
10/10/14 - $2.19
Market Cap
53.5M
Average Volume 10 Days
12.5K
EPS TTM
$-0.23
Shares Outstanding
22.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for UROPLASTY INC (UPI)

Related News

No related news articles were found.

uroplasty inc (UPI) Related Businessweek News

No Related Businessweek News Found

uroplasty inc (UPI) Details

Uroplasty, Inc., a medical device company, develops, manufactures, and markets products for the treatment of voiding dysfunctions primarily in the United States. It principally offers Urgent PC Neuromodulation system, a minimally-invasive, neuromodulation system that delivers percutaneous tibial nerve stimulation for office-based treatment of overactive bladder and the associated symptoms of urinary urgency, urinary frequency, and urge incontinence. The company also provides Macroplastique implants, an injectable and urethral bulking agent for the treatment of adult female stress urinary incontinence due to intrinsic sphincter deficiency, as well as for the treatment of male stress incontinence, fecal incontinence, vocal cord rehabilitation, and vesicoureteral reflux. In addition, it offers Macroplastique products for treatment of vesicoureteral reflux; Urgent PC System for the treatment of fecal incontinence; PTQ Implants, which provides a minimally-invasive, soft-textured permanent implant for treatment of fecal incontinence; and VOX Implants, a silicone elastomer bulking material for vocal cord rehabilitation applications, as well as distributes wound care products. The company sells its products primarily to urologists, urogynecologists, and gynecologists through a direct sales organization in the United Kingdom, the Netherlands, Switzerland, and the Nordic countries, as well as through distributors in other markets. Uroplasty, Inc. was incorporated in 1992 and is headquartered in Minnetonka, Minnesota.

113 Employees
Last Reported Date: 06/9/14
Founded in 1992

uroplasty inc (UPI) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $589.2K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $212.7K
Vice President of Corporate Development
Total Annual Compensation: $195.1K
Senior Vice President of Global Sales and Mar...
Total Annual Compensation: $332.3K
Compensation as of Fiscal Year 2014.

uroplasty inc (UPI) Key Developments

Uroplasty, Inc. Presents at Canaccord Genuity 2014 Medical Technologies & Diagnostics Forum, Nov-20-2014 04:00 PM

Uroplasty, Inc. Presents at Canaccord Genuity 2014 Medical Technologies & Diagnostics Forum, Nov-20-2014 04:00 PM. Venue: The Westin Grand Central, New York, New York, United States. Speakers: Robert C.E. Kill, Chairman, Chief Executive Officer and President.

Uroplasty Mulls Acquisitions

Uroplasty, Inc. (NasdaqCM:UPI) intends to pursue acquisitions. Uroplasty has filed a Shelf Registration to raise $50 million. The company plans to use the net proceeds we receive from the sale of the securities for general corporate purposes, which may include, among other things, working capital, capital expenditures or the financing of possible acquisitions.

Uroplasty, Inc. Announces Unaudited Consolidated Earnings Results for Second Quarter and Six Months Ended Sept. 30, 2014; Reaffirms Guidance for 2015

Uroplasty, Inc. announced unaudited consolidated earnings results for second quarter and six months ended Sept. 30, 2014. For the quarter, the company reported net sales of $6,454,630, operating loss of $1,064,857, loss before income taxes of $1,065,214, net loss of $1,080,246 or $0.05 per basic and diluted share, compared to the net sales of $5,976,875, operating loss of $1,915,250, loss before income taxes of $1,911,113, net loss of $1,927,480 or $0.09 per basic and diluted share for the same quarter a year ago. Non-GAAP operating loss was $661,000 compared to $917,000 a year ago. The decrease in non-GAAP operating loss for the three months ended September 30, 2014 over the corresponding period a year ago is attributed to the increase in sales and gross profit percent, offset slightly by the increase in operating spending. For the year to date, the company reported net sales of $12,839,259, operating loss of $3,239,298, loss before income taxes of $3,235,732, net loss of $3,270,579 or $0.15 per basic and diluted share, net cash used in operating activities of $2,475,749, purchases of property, plant and equipment of $128,041 compared to the net sales of $11,817,716, operating loss of $3,516,936, loss before income taxes of $3,506,230, net loss of $3,536,772 or $0.17 per basic and diluted share, net cash used in operating activities of $2,242,895, purchases of property, plant and equipment of $208,768 for the same period a year ago. The non-GAAP operating loss for the six months ended September 30, 2014 includes an increase in operating spending, offset by the increase in net sales and gross profit percent. For the full-year Fiscal 2015, the Company expects total revenue growth in the range of 9 to 12%, approximately 15% growth in global Urgent PC sales, and slightly higher gross margins on a year-over-year basis.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
UPI:US $2.42 USD +0.005

UPI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bacterin International Holdings Inc $2.91 USD -0.13
Cardica Inc $0.62 USD +0.0498
Cytori Therapeutics Inc $0.41 USD +0.0008
Stereotaxis Inc $1.80 USD +0.04
Vision Sciences Inc/DE $1.05 USD +0.0199
View Industry Companies
 

Industry Analysis

UPI

Industry Average

Valuation UPI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.0x
Price/Book 5.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact UROPLASTY INC, please visit www.uroplasty.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.